Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1901. Should the French breast cancer screening programme be extended to women aged 40-49? Update

Should the French breast cancer screening programme be extended to women aged 40-49? Update Should the French breast cancer screening programme be extended to women aged 40-49? Update Should the French breast cancer screening programme be extended to women aged 40-49? Update L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES). Should the French breast cancer screening programme be extended to women aged 40-49? Update. Paris: L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) 2004: 96 Authors' objectives This study aimed to assess whether the French breast cancer screening programme should be extended to women aged 40-49 with no history of breast cancer or hereditary risk, using WHO criteria

Health Technology Assessment (HTA) Database.2004

1903. Breast ductal lavage and fiberoptic ductoscopy for breast cancer diagnosis and screening

Breast ductal lavage and fiberoptic ductoscopy for breast cancer diagnosis and screening Breast ductal lavage and fiberoptic ductoscopy for breast cancer diagnosis and screening Breast ductal lavage and fiberoptic ductoscopy for breast cancer diagnosis and screening Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Breast ductal lavage and fiberoptic ductoscopy (...) for breast cancer diagnosis and screening. Lansdale: HAYES, Inc.. Directory Publication. 2004 Authors' objectives Breast ductal lavage (DL) and fiberoptic ductoscopy (FDS) are used to evaluate patients at risk for breast cancer. DL involves collection of breast ductal epithelial cells for cytological analysis, and FDS involves direct visualization of the breast duct lining with cytology or biopsy of abnormalities. These procedures are intended to be used in conjunction with clinical breast examination

Health Technology Assessment (HTA) Database.2004

1905. Breast MRI for detection or diagnosis of primary or recurrent breast cancer

Breast MRI for detection or diagnosis of primary or recurrent breast cancer Breast MRI for detection or diagnosis of primary or recurrent breast cancer Breast MRI for detection or diagnosis of primary or recurrent breast cancer BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation (...) Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Breast MRI for detection or diagnosis of primary or recurrent breast cancer. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 19(01). 2004 Authors' objectives The objective of this Assessment is to evaluate the clinical effectiveness of magnetic resonance imaging (MRI) of the breast to detect

Health Technology Assessment (HTA) Database.2004

1906. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda (R)) for locally advanced and/or metastatic breast cancer

Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda (R)) for locally advanced and/or metastatic breast cancer Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda (R)) for locally advanced and/or metastatic breast cancer Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda (R)) for locally advanced and/or metastatic breast cancer Jones L, Hawkins N, Westwood M, Wright K (...) , Richardson G, Riemsma R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jones L, Hawkins N, Westwood M, Wright K, Richardson G, Riemsma R. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda (R)) for locally advanced and/or metastatic breast cancer. Health Technology Assessment 2004; 8(5): 1-156 Authors

Health Technology Assessment (HTA) Database.2004

1908. The Role of Taxanes in Neoadjuvant Chemotherapy for Women with Non-Metastatic Breast Cancer

The Role of Taxanes in Neoadjuvant Chemotherapy for Women with Non-Metastatic Breast Cancer

Cancer Care Ontario2004

1909. Anastrozole (Arimidex) - Postmenopausal women with oestrogen receptor positive early invasive breast cancer

Anastrozole (Arimidex) - Postmenopausal women with oestrogen receptor positive early invasive breast cancer Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6997 Fax 0141 248 3778 E-mail jmitchell@htbs.org.uk Chairman Professor David Lawson Scottish Medicines Consortium Anastrozole (Arimidex Ò ) No. 90/04 AstraZeneca UK Ltd Indication: Adjuvant treatment of postmenopausal women with oestrogen receptor (ER) positive early invasive breast cancer who are unable (...) to take tamoxifen because of a high risk of thromboembolism or endometrial abnormalities. Summary of Recommendation 8 February, 2004 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows: Advice: following a full submission. Anastrozole (Arimidex ® ) is accepted for restricted use within NHS Scotland for the adjunctive treatment of early breast cancer

Scottish Medicines Consortium2004

1910. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer

Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page

NIHR HTA programme2004

1912. Treatment for women with stage III or locally advanced breast cancer

Treatment for women with stage III or locally advanced breast cancer Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer Information for… Search for Keyword: Submit , , , , , , for The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer Dr. Shenkier is with the BC Cancer Agency–Vancouver Cancer Centre and is Clinical Assistant Professor in the Department (...) of Medicine, University of British Columbia, Vancouver, BC; Dr. Weir is with the BC Cancer Agency–Vancouver Cancer Centre and is Clinical Associate Professor in the Department of Surgery, University of British Columbia, Vancouver, BC; Dr. Levine is Professor in the Departments of Clinical Epidemiology and Biostatistics and of Medicine and is the Buffet Taylor Chair in Breast Cancer Research, McMaster University, Hamilton, Ont.; Dr. Olivotto is with the BC Cancer Agency–Vancouver Island Cancer Centre

CMA Infobase (Canada)2004 Full Text: Link to full Text with Trip Pro

1913. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped.

HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. 14962527 2004 02 13 2004 03 16 2015 06 16 1474-547X 363 9407 2004 Feb 07 Lancet (London, England) Lancet HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. 453-5 In the 1990s, two randomised clinical trials started in Scandinavia addressing whether hormone replacement therapy (HRT) is safe for women with previous breast (...) cancer. We report the findings of the safety analysis in HABITS (hormonal replacement therapy after breast cancer--is it safe?), an open randomised clinical trial with allocation to either HRT or best treatment without hormones. The main endpoint was any new breast cancer event. All analyses were done according to intention-to-treat. Until September, 2003, 434 women were randomised; 345 had at least one follow-up report. After a median follow-up of 2.1 years, 26 women in the HRT group and seven

Lancet2004

1914. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. 15014181 2004 03 11 2004 03 15 2016 11 24 1533-4406 350 11 2004 Mar 11 The New England journal of medicine N. Engl. J. Med. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. 1081-92 Tamoxifen, taken for five years, is the standard adjuvant treatment for postmenopausal women with primary (...) , estrogen-receptor-positive breast cancer. Despite this treatment, however, some patients have a relapse. We conducted a double-blind, randomized trial to test whether, after two to three years of tamoxifen therapy, switching to exemestane was more effective than continuing tamoxifen therapy for the remainder of the five years of treatment. The primary end point was disease-free survival. Of the 4742 patients enrolled, 2362 were randomly assigned to switch to exemestane, and 2380 to continue to receive

NEJM2004

1915. Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial.

Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. 15280341 2004 07 28 2004 08 02 2016 10 17 1538-3598 292 4 2004 Jul 28 JAMA JAMA Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. 435-41 The long-term results of randomized trials have demonstrated equivalent survival rates for mastectomy and breast-conserving therapy for the treatment of early stage breast cancer (...) in the study. Of the 208 eligible women with newly diagnosed clinical stage I or II breast cancer seen by study surgeons, 201 agreed to be evaluated: 94 were assigned to the decision board and 107 to usual practice. Patients were recruited from November 1999 to April 2002. The decision board is a decision aid designed to help physicians inform their patients about different treatment options and to enable patients to express a preference for treatment. Patient knowledge about the surgical treatment

JAMA2004

1916. Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial.

Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. 15280342 2004 07 28 2004 08 02 2017 02 19 1538-3598 292 4 2004 Jul 28 JAMA JAMA Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. 442-52 As the availability of and demand for genetic testing for hereditary (...) cancers increases in primary care and other clinical settings, alternative or adjunct educational methods to traditional genetic counseling will be needed. To compare the effectiveness of a computer-based decision aid with standard genetic counseling for educating women about BRCA1 and BRCA2 genetic testing. Randomized controlled trial conducted from May 2000 to September 2002. Outpatient clinics offering cancer genetic counseling at 6 US medical centers enrolled 211 women with personal or family

JAMA2004 Full Text: Link to full Text with Trip Pro

1917. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer.

Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. 15342804 2004 09 02 2004 09 07 2013 11 21 1533-4406 351 10 2004 Sep 02 The New England journal of medicine N. Engl. J. Med. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. 963-70 We determined the effect of breast irradiation plus tamoxifen on disease-free survival and local relapse in women 50 years of age or older who had T1 or T2 (...) node-negative breast cancer. Between December 1992 and June 2000, 769 women with early breast cancer (tumor diameter, 5 cm or less) were randomly assigned to receive breast irradiation plus tamoxifen (386 women) or tamoxifen alone (383 women). The median follow-up was 5.6 years. The rate of local relapse at five years was 7.7 percent in the tamoxifen group and 0.6 percent in the group given tamoxifen plus irradiation (hazard ratio, 8.3; 95 percent confidence interval, 3.3 to 21.2; P<0.001

NEJM2004

1918. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. 15342805 2004 09 02 2004 09 07 2014 02 03 1533-4406 351 10 2004 Sep 02 The New England journal of medicine N. Engl. J. Med. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. 971-7 In women 70 years of age or older who have early breast cancer, it is unclear whether lumpectomy plus tamoxifen is as effective as lumpectomy (...) followed by tamoxifen plus radiation therapy. Between July 1994 and February 1999, we randomly assigned 636 women who were 70 years of age or older and who had clinical stage I (T1N0M0 according to the tumor-node-metastasis classification), estrogen-receptor-positive breast carcinoma treated by lumpectomy to receive tamoxifen plus radiation therapy (317 women) or tamoxifen alone (319 women). Primary end points were the time to local or regional recurrence, the frequency of mastectomy for recurrence

NEJM2004

1919. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. 15591335 2004 12 30 2005 01 14 2015 11 19 1533-4406 351 27 2004 Dec 30 The New England journal of medicine N. Engl. J. Med. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. 2817-26 The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical (...) and histopathological measures. We tested whether the results of a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of 21 prospectively selected genes in paraffin-embedded tumor tissue would correlate with the likelihood of distant recurrence in patients with node-negative, tamoxifen-treated breast cancer who were enrolled in the National Surgical Adjuvant Breast and Bowel Project clinical trial B-14. The levels of expression of 16 cancer-related genes and 5 reference genes were used

NEJM2004

1920. Interstitial laser therapy for breast cancer (IPG89)

Interstitial laser therapy for breast cancer (IPG89) Interstitial laser therapy for breast cancer | Guidance and guidelines | NICE Interstitial laser therapy for breast cancer Interventional procedures guidance [IPG89] Published date: September 2004 Share Save Guidance and for this guidance. Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected

National Institute for Health and Clinical Excellence - Interventional Procedures2004